WuXi Biologics Achieves ISO 13485 Certification for Drug-Device Combination Products Manufacturing

Key Takeaways

• WuXi Biologics achieved ISO 13485:2016 Medical Device Quality Management System certification with zero non-conformities
• Company becomes among the first in China’s drug-device combination products sector to obtain this certification
• Certification strengthens WuXi’s capabilities in developing and manufacturing complex therapeutic products that combine drugs with medical devices

---

WuXi Biologics Sets New Standard with Zero-Defect ISO Certification

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced on April 14, 2026, that it has successfully achieved ISO 13485:2016 Medical Device Quality Management System certification with zero non-conformities. This milestone positions the company among the first in China’s drug-device combination products sector to obtain this prestigious certification.

Strengthening Drug-Device Combination Capabilities

The ISO 13485:2016 certification provides a structured framework to ensure safety, effectiveness, and regulatory compliance in medical device manufacturing. For WuXi Biologics, this achievement significantly enhances its ability to develop and manufacture drug-device combination products, which represent a rapidly growing segment in the pharmaceutical industry.

Drug-device combination products integrate pharmaceutical compounds with medical devices to deliver targeted therapies more effectively. Examples include pre-filled syringes, auto-injectors, and implantable drug delivery systems. These products require specialized manufacturing expertise that combines pharmaceutical and medical device quality standards.

Market Impact and Industry Implications

This certification comes at a crucial time as the global drug-device combination products market continues expanding, driven by increasing demand for patient-friendly delivery systems and personalized medicine solutions. WuXi Biologics’ achievement with zero non-conformities demonstrates exceptional quality management capabilities, potentially attracting more international clients seeking reliable manufacturing partners.

The certification also strengthens China’s position in the global pharmaceutical manufacturing landscape, as regulatory authorities worldwide increasingly recognize ISO 13485 as a benchmark for medical device quality management.

Strategic Advantages for Clients

For pharmaceutical companies partnering with WuXi Biologics, this certification means access to manufacturing capabilities that meet the highest international standards for drug-device combination products. The zero non-conformities achievement indicates robust quality control processes, potentially reducing regulatory risks and accelerating time-to-market for complex therapeutic products.

---

Frequently Asked Questions

What is ISO 13485 certification and why is it important?

ISO 13485:2016 is an international standard for medical device quality management systems. It ensures companies have robust processes for designing, manufacturing, and distributing medical devices safely and effectively, meeting regulatory requirements worldwide.

What are drug-device combination products?

Drug-device combination products integrate pharmaceutical compounds with medical devices, such as pre-filled syringes, auto-injectors, or implantable delivery systems. They require specialized manufacturing that meets both pharmaceutical and medical device quality standards.

How does this certification benefit patients?

The certification ensures WuXi Biologics can manufacture drug-device combination products to the highest safety and quality standards, potentially leading to more effective, user-friendly treatments and faster access to innovative therapies.

Related coverage

• Drug Discovery Technology Market Size Tops USD 80.27 Billion by 2035
• TGA Australia drug approval pharmaceutical: what the regulator is
• PMDA Regulatory Updates: New Orphan Drug Portal and ASEAN Symposium Open